Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 11, 2009

Stemgent Licenses TET's Stem Cell Reprogramming Reagents

  • Stemgent entered into an agreement to market reagents based on TET Systems’ technology for creating inducible stem cells. Stemgent will apply Tet Technology to its portfolio of viral vector systems for induced pluripotent stem (iPS) cells.

    Tet Technology is based on regulatory components of the E. coli tetracycline-resistance operon. Once established in the cell line, the inducer doxycycline, a tetracycline derivative, will control the system in a dose-dependent manner. This will allow researchers to precisely modulate the expression levels of target genes and other transcription factors identified as important in the generation of iPS cells, according to the firms.

     

    ---

    To comment on this story, go to BLOGbiotech.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »